Large-scale testing (Phase 3)Looking for participantsNCT06357533
What this trial is testing
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 675